Anmelden Kostenlos registrieren

Last updated: 15 November 2021 at 7:43pm EST

Aditya P. Mohanty Net Worth



Mr Mohanty PROG stock SEC Form 4 insiders trading

Mr has made over 7 trades of the Progenity stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 4,687 units of PROG stock worth $4,125 on 10 July 2018.

The largest trade he's ever made was exercising 18,750 units of Progenity stock on 10 April 2017 worth over $16,500. On average, Mr trades about 3,549 units every 33 days since 2016. As of 10 July 2018 he still owns at least 103,005 units of Progenity stock.

You can see the complete history of Mr Mohanty stock trades at the bottom of the page.





Mr. Aditya P. Mohanty biography

Aditya P. Mohanty is the CEO & Director at Progenity.



How old is Mr Mohanty?

Mr Mohanty is 54, he's been the CEO & Director of Progenity since . There are 3 older and 4 younger executives at Progenity. The oldest executive at Progenity, Inc. is George Gianakopoulos, 59, who is the Sr. VP of Sales.

What's Mr Mohanty's mailing address?

Aditya's mailing address filed with the SEC is 1010 Atlantic Ave #102, Alameda, CA 94501, USA.

Insiders trading at Progenity

Over the last 4 years, insiders at Progenity have traded over $0 worth of Progenity stock and bought 34,001,547 units worth $176,045,049 . The most active insiders traders include Capital Management, Lp Ferr..., Opportunities Fund (A) Lp A... und Opportunities Fund (A) Lp A.... On average, Progenity executives and independent directors trade stock every 24 days with the average trade being worth of $1,994,758. The most recent stock trade was executed by Capital Management, Lp Ferr... on 14 June 2021, trading 8,097,166 units of PROG stock currently worth $20,000,000.



What does Progenity do?

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.



What does Progenity's logo look like?

Progenity, Inc. logo

Progenity executives and stock owners

Progenity executives and other stock owners filed with the SEC include: